InflaRx: EMA Reviews MAA For Vilobelimab For Critically Ill COVID-19 Patients; Stock Up In Premarket
InflaRx N.V. (IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, Wednesday said the European Medicines Agency or EMA has validated its Marketing […]
Continue reading »